

January 30, 2003

For Immediate Release

Company: Taisho Pharmaceutical Co., Ltd.  
(First Section of TSE: Code 4535)  
Head Office: 24-1, Takada 3-chome  
Toshima-ku, Tokyo  
Representative: Akira Uehara, President  
Contact: Takashi Shibata, Manager  
Public Relations Section  
(Tel: 81-3-3985-1115)

## Taisho Revises Earnings Forecasts for FY2003

Taisho Pharmaceutical Co., Ltd. announced that, based on recent business trends, it has revised its earnings forecasts for the full year of fiscal 2003 (April 1, 2003 to March 31, 2004). The previous forecasts were announced on November 10, 2003.

### 1. Consolidated Forecasts of Business Results

(Millions of yen, %)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)	298,000	54,800	60,200	34,800
Revised Forecast (B)	290,000	53,000	58,000	34,000
Change (B-A)	-8,000	-1,800	-2,200	-800
Change (%)	-2.7	-3.3	-3.7	-2.3
Fiscal 2002	274,077	54,394	60,857	35,392

### 2. Non-Consolidated Forecasts of Business Results

(Millions of yen, %)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)	247,000	55,000	60,500	35,300
Revised Forecast (B)	243,000	54,000	59,000	35,000
Change (B-A)	-4,000	-1,000	-1,500	-300
Change (%)	-1.6	-1.8	-2.5	-0.8
Fiscal 2002	268,920	54,494	60,405	35,136

Note: From April 1, 2003, sales in Japan of Taisho's prescription pharmaceuticals are conducted through Taisho Toyama Pharmaceutical Co., Ltd.

### **3. Reasons for the Revision**

Conditions in the Self-Medication market continued to deteriorate impacted by the prolonged market slump and increased competition. Despite the onset of winter, traditionally a period of peak demand, early sales of medications for nasal allergy and cold remedies were slow. Despite the start-up of Taisho Toyama Pharmaceutical in April 2003, sales in the Prescription Pharmaceutical Operation Group fell below forecasts with contributions and a positive flow-on effect taking longer than initially anticipated.

As a result, the Company has revised its consolidated and non-consolidated forecasts announced on November 10, 2003.